Paragon 28 (FNA) Stock Price, News & Analysis

Company Overview

Paragon 28, Inc. (NYSE: FNA) is a medical device company specializing in comprehensive solutions for foot and ankle surgery. Headquartered in Englewood, Colorado, the company develops, manufactures, and markets a diverse range of implants, instruments and digital platforms to support orthopedic surgeons. Since its founding in 2019, Paragon 28 has focused on delivering clinically driven products designed to address both routine and complex pathologies of the lower extremity.

The company’s product portfolio includes plating systems, intramedullary nails, compression staples, external fixation devices and patient-specific instrumentation. Paragon 28 also offers proprietary digital preoperative planning and post-operative monitoring tools that allow surgeons to tailor treatment plans, optimize implant selection and track patient outcomes. These integrated solutions are intended to enhance surgical precision, reduce operating room time and improve overall case efficiency.

With a global footprint, Paragon 28 serves hospitals, ambulatory surgery centers and physician practices across North America, Europe, Asia-Pacific and the Middle East. The company distributes its products through a combination of direct sales teams and regional distribution partners, investing in clinical education programs, cadaver labs and advisory boards to support surgeon training and adoption. Paragon 28’s international expansion has been driven by strategic partnerships and targeted product launches aligned with regional regulatory requirements.

Under the leadership of President and Chief Executive Officer Michael Macioci, Paragon 28 emphasizes a culture of innovation and collaboration. The company’s executive team and board of directors include experienced professionals from the orthopedic and medical technology sectors. Paragon 28 continues to pursue research and development initiatives aimed at refining surgical workflows and advancing next-generation implant technologies, while maintaining close engagement with key opinion leaders and academic institutions.

Key Stats

• Today's Range: $13.07 to $13.11
• 50-Day Range: $13.11 to $13.11
• 52-Week Range: $4.65 to $13.13
• Volume: 19.38 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $1.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.75
• Consensus Rating: Hold

Paragon 28 Stock Analysis - MarketRank™

Paragon 28 scored higher than 11% of companies evaluated by MarketBeat, and ranked 873rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Paragon 28 has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Paragon 28 has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Paragon 28 are expected to grow in the coming year, from ($0.64) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Paragon 28 is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Paragon 28 is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Paragon 28 has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FNA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Paragon 28 does not currently pay a dividend.

Dividend Growth

Paragon 28 does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for FNA.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Paragon 28 has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Paragon 28 insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.32% of the stock of Paragon 28 is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.57% of the stock of Paragon 28 is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FNA Stock Analysis - Frequently Asked Questions

How have FNA shares performed this year?

Paragon 28's stock was trading at $10.33 at the beginning of 2025. Since then, FNA stock has increased by 26.9% and is now trading at $13.1050.

How were Paragon 28's earnings last quarter?

Paragon 28, Inc. (NYSE:FNA) issued its earnings results on Thursday, March, 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company had revenue of $71.75 million for the quarter, compared to analysts' expectations of $70.81 million. Paragon 28 had a negative trailing twelve-month return on equity of 37.90% and a negative net margin of 25.31%.

When did Paragon 28 IPO?

Paragon 28 (FNA) raised $125 million in an IPO on Friday, October 15th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities and Piper Sandler acted as the underwriters for the IPO and Canaccord Genuity, JMP Securities and Needham & Company were co-managers.

How do I buy shares of Paragon 28?

Shares of FNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Paragon 28 own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Paragon 28 investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 7/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:FNA
• CIK: 1531978
• Web: www.paragon28.com
• Phone: 720-912-1332
• Fax: N/A
• Employees: 343,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.75
• High Stock Price Target: $13.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: -2.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.53 million
• Net Margins: -25.31%
• Pretax Margin: -26.58%
• Return on Equity: -37.90%
• Return on Assets: -18.22%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 3.50
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $256.18 million
• Price / Sales: 4.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.05 per share
• Price / Book: 6.39

Miscellaneous

• Outstanding Shares: 83,937,000
• Free Float: 70,894,000
• Market Cap: $1.10 billion
• Optionable: Optionable
• Beta: 1.47